ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 852,09
-0,04%
Dow Jones
44 421,91
-0,28%
DAX
21 403,52
-0,01%
Brent Oil
74,99
-0,49%
Bitcoin
98 708,04
-2,67%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Vaccinex Inc (VCNX)

  7. Vaccinex Inc (VCNX) Actualités

VCNX

Vaccinex (VCNX)

Vaccinex Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:VCNX
DateHeureSourceTitreSymboleSociété
17/12/202415h32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VCNXVaccinex Inc
17/12/202415h00GlobeNewswire Inc.Vaccinex Announces Receipt of Delisting Notification from NasdaqNASDAQ:VCNXVaccinex Inc
18/11/202422h15Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:VCNXVaccinex Inc
18/11/202422h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VCNXVaccinex Inc
18/11/202414h30GlobeNewswire Inc.Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VCNXVaccinex Inc
14/11/202422h45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VCNXVaccinex Inc
14/11/202421h39Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:VCNXVaccinex Inc
07/11/202414h30GlobeNewswire Inc.Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITCNASDAQ:VCNXVaccinex Inc
05/11/202414h30GlobeNewswire Inc.Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual MeetingNASDAQ:VCNXVaccinex Inc
31/10/202415h00GlobeNewswire Inc.Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, SpainNASDAQ:VCNXVaccinex Inc
25/10/202422h11Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VCNXVaccinex Inc
25/10/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VCNXVaccinex Inc
24/10/202414h30GlobeNewswire Inc.Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024NASDAQ:VCNXVaccinex Inc
16/10/202422h44Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VCNXVaccinex Inc
27/09/202422h11Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:VCNXVaccinex Inc
18/09/202414h30GlobeNewswire Inc.Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross ProceedsNASDAQ:VCNXVaccinex Inc
14/08/202414h30GlobeNewswire Inc.Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development PartnershipNASDAQ:VCNXVaccinex Inc
31/07/202415h00GlobeNewswire Inc.Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s DiseaseNASDAQ:VCNXVaccinex Inc
17/07/202414h00GlobeNewswire Inc.Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024NASDAQ:VCNXVaccinex Inc
06/06/202414h30GlobeNewswire Inc.Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s DiseaseNASDAQ:VCNXVaccinex Inc
16/05/202400h00GlobeNewswire Inc.Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VCNXVaccinex Inc
14/05/202422h36Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:VCNXVaccinex Inc
10/05/202418h33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VCNXVaccinex Inc
08/05/202418h29Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:VCNXVaccinex Inc
02/04/202414h30GlobeNewswire Inc.Vaccinex Reports 2023 Financial Results and Provides Corporate UpdateNASDAQ:VCNXVaccinex Inc
27/03/202413h30GlobeNewswire Inc.Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:VCNXVaccinex Inc
21/02/202414h00GlobeNewswire Inc.Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyNASDAQ:VCNXVaccinex Inc
15/02/202414h00GlobeNewswire Inc.Vaccinex, Inc. Announces Reverse Stock SplitNASDAQ:VCNXVaccinex Inc
13/02/202422h15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:VCNXVaccinex Inc
09/02/202422h08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VCNXVaccinex Inc
 Showing the most relevant articles for your search:NASDAQ:VCNX

Dernières Valeurs Consultées

NASDAQ
FCQEX
Bmo Private Us Special E...
NASDAQ
FELQX
Bmo Sustainable Income P...
BOV
MCOR34R
Moodys
NASDAQ
FCLDX
Beutel Goodman Short Ter...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces